Cereno Scientific is a clinical-stage biotech developing disease-modifying therapies for rare cardiovascular and pulmonary conditions. Its lead programs use HDAC inhibition and epigenetic modulation—notably CS1 for pulmonary arterial hypertension—with additional candidates aimed at related cardiopulmonary and thrombotic indications. The company targets areas with high unmet medical need where current options remain limited.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -25 | — |
| Q2 2025 | 0 | — | -26.6 | — |
| Q3 2025 | 0 | — | -21.3 | — |
| Q4 2025 | 0 | — | -44.7 | — |
| Q1 2026 | 0 | — | -28.6 | — |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Paxman AB (publ) (PAX), Cavotec Group AB (CCC), Veteranpoolen AB (publ) (VPAB B), Annehem Fastigheter AB (ANNE B), Green Landscaping Group AB (publ) (GREEN), Lea Bank AB (publ) (LEA)